The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

RCONHOR'     N-hydroxymethanamide

Synonyms: CHEBI:61398, CHEBI:75606, WLN: VHMQ, NSC-101638, RC(O)NHOR', ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

High impact information on N-hydroxyformamide

  • We have previously reported an N-formylhydroxylamine-based, metal-chelating macrocyclic PDF inhibitor, in which the P(1)' and P(3)' side chains are covalently joined [1].
  • A program to improve upon the in vitro, in vivo, and physicochemical properties of N-hydroxyformamide TACE inhibitor GW 3333 (1) is described [2].
  • CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans [3].
  • N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution [4].
 

Gene context of N-hydroxyformamide

  • A series of N-hydroxyformamide tumor necrosis factor-alpha converting enzyme (TACE)/matrix metalloprotease (MMP) inhibitors were evaluated for their potential to induce human cytochrome P450 3A (CYP3A) [3].

References

  1. Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size. Hu, X., Nguyen, K.T., Jiang, V.C., Lofland, D., Moser, H.E., Pei, D. J. Med. Chem. (2004) [Pubmed]
  2. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Rabinowitz, M.H., Andrews, R.C., Becherer, J.D., Bickett, D.M., Bubacz, D.G., Conway, J.G., Cowan, D.J., Gaul, M., Glennon, K., Lambert, M.H., Leesnitzer, M.A., McDougald, D.L., Moss, M.L., Musso, D.L., Rizzolio, M.C. J. Med. Chem. (2001) [Pubmed]
  3. CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans. Tippin, T.K., Hamilton, G., Moore, L., Beaudet, E.J., Jolley, S., Brodie, T.A., Andrews, R.C., Becherer, J.D., McDougald, D.L., Gaul, M.D., Hoivik, D.J., Mellon-Kusibab, K., Lehmann, J., Kliewer, S., Novick, S., Laethem, R., Zhao, Z., LeCluyse, E.L. Drug Metab. Dispos. (2003) [Pubmed]
  4. N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution. Musso, D.L., Andersen, M.W., Andrews, R.C., Austin, R., Beaudet, E.J., Becherer, J.D., Bubacz, D.G., Bickett, D.M., Chan, J.H., Conway, J.G., Cowan, D.J., Gaul, M.D., Glennon, K.C., Hedeen, K.M., Lambert, M.H., Leesnitzer, M.A., McDougald, D.L., Mitchell, J.L., Moss, M.L., Rabinowitz, M.H., Rizzolio, M.C., Schaller, L.T., Stanford, J.B., Tippin, T., Warner, J.R., Whitesell, L.G., Wiethe, R.W. Bioorg. Med. Chem. Lett. (2001) [Pubmed]
 
WikiGenes - Universities